FMP
Chiasma, Inc.
CHMA
NASDAQ
Inactive Equity
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
3.76 USD
-0.24000001 (-6.38%)
About
ceo
Mr. Raj Kannan
sector
Healthcare
industry
Biotechnology
website
http://www.chiasma.com
exchange
NASDAQ
Description
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
CIK
0001339469
ISIN
US16706W1027
CUSIP
16706W102
Address
140 Kendrick Street, Building ...
Phone
16179285300
Country
US
Employee
84
IPO Date
Jul 16, 2015
Key Executives
